Goal of this study

To treat Alzheimer’s disease.


Alzheimer’s disease is a brain disease that gradually destroys memory and thinking skills. This study will investigate the safety, tolerability and efficacy of a drug named ‘RPh201’ in patients with mild or moderate Alzheimer’s disease. RPh201 will be given to the patient subcutaneously which means through injection under the skin. RPh201 will be administered twice per week for a period of 26 weeks.

Who can participate in this study?

Patients who have been diagnosed with mild or moderate Alzheimer’s disease and who are 65 years and older may be eligible to participate in this study. This study accepts both men and women and does not accept healthy volunteers.

Important: Additional eligibility criteria apply and the patient’s record will be verified by the study doctor (with the patient’s approval) to confirm eligibility.

Clinicaltrials.gov identifier: NCT03462121

Contact Information

To know if you're eligible to participate in this trial, please fill-up the form below and we will contact you shortly.